Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.

Titel:: Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.
Dokumenttyp:: Published Erratum
Autor(en):: Kundranda, M; Gracian, A C; Zafar, S F; Meiri, E; Bendell, J; Algül, H; Rivera, F; Ahn, E R; Watkins, D; Pelzer, U; Charu, V; Zalutskaya, A; Kuesters, G; Pipas, J M; Santillana, S; Askoxylakis, V; Ko, A H
Zeitschriftentitel:: Ann Oncol
Jahr:: 2020
Band / Volume:: 31
Heft / Issue:: 8
Volltext / DOI:: doi:10.1016/j.annonc.2020.05.011
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/32507672
Print-ISSN:: 0923-7534
TUM Einrichtung:: Lehrstuhl für Tumormetabolismus (Prof. Algül)
BibTeX

Vorkommen: